Pharmazz
Pharmazz, Inc. is a commercial-stage biopharmaceutical company focused on discovery, development, regulatory progression, and commercialization of first-in-class therapeutics for critical care and hospital medicine. The company develops small-molecule receptor agonists across neurological and resuscitative indications, operates clinical development and R&D activities in the US and India, and has launched at least one marketed product in India.
Industries
Nr. of Employees
medium (51-250)
Patents
Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
US-12629406-B2
View Details
Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
US-12629406-B2
View DetailsProducts
Sovateltide (lead neurovascular candidate)
A selective endothelin-B receptor agonist developed for neurovascular repair and neuroregeneration. Studied in preclinical models for increased cerebral blood flow, anti-apoptotic activity, mitochondrial biogenesis, neurogenesis and angiogenesis; advanced through Phase I–III clinical studies and marketed in India under a regional brand name.
Centhaquine (resuscitative agent)
A resuscitative small-molecule agent acting via alpha-2 adrenergic pathways to increase venous return and cardiac output, developed for hypovolemic shock and investigated for ARDS, septic shock, AKI and related critical care indications. Commercialized in India.
Lyfaquin
Centhaquine (Lyfaquin) is a highly effective resuscitative agent developed to treat hypovolemic shock by enhancing venous return and returning blood to active circulation.
Centhaquine
A novel resuscitative agent that increases cardiac output and reverses shock without inducing dangerous arterial constriction, delivered via a standard peripheral IV.
Tycamzzi
Sovateltide (Tycamzzi) is a novel, first-in-class neurovascular agent and endothelin-B receptor agonist currently undergoing clinical trials and commercialized for ischemic stroke and other neurodegenerative indications.
Sovateltide
Sovateltide is an endothelin-B (ETB) receptor agonist researched and developed for the treatment of Alzheimer's disease to promote neurogenesis, angiogenesis, and repair damaged brain tissue.
Sovateltide (lead neurovascular candidate)
A selective endothelin-B receptor agonist developed for neurovascular repair and neuroregeneration. Studied in preclinical models for increased cerebral blood flow, anti-apoptotic activity, mitochondrial biogenesis, neurogenesis and angiogenesis; advanced through Phase I–III clinical studies and marketed in India under a regional brand name.
Centhaquine (resuscitative agent)
A resuscitative small-molecule agent acting via alpha-2 adrenergic pathways to increase venous return and cardiac output, developed for hypovolemic shock and investigated for ARDS, septic shock, AKI and related critical care indications. Commercialized in India.
Lyfaquin
Centhaquine (Lyfaquin) is a highly effective resuscitative agent developed to treat hypovolemic shock by enhancing venous return and returning blood to active circulation.
Centhaquine
A novel resuscitative agent that increases cardiac output and reverses shock without inducing dangerous arterial constriction, delivered via a standard peripheral IV.
Tycamzzi
Sovateltide (Tycamzzi) is a novel, first-in-class neurovascular agent and endothelin-B receptor agonist currently undergoing clinical trials and commercialized for ischemic stroke and other neurodegenerative indications.
Sovateltide
Sovateltide is an endothelin-B (ETB) receptor agonist researched and developed for the treatment of Alzheimer's disease to promote neurogenesis, angiogenesis, and repair damaged brain tissue.
Expertise Areas
- Critical care therapeutics development
- Clinical trial management (Phase I–IV, multi-center)
- Regulatory strategy and submissions (IND, SPA, NDA)
- Translational neuropharmacology
Key Technologies
- Endothelin-B receptor agonist therapeutics
- Alpha-2 adrenergic receptor agonist therapeutics
- Intravenous hospital-administered formulation development
- Rodent and large-animal models for stroke and shock
News & Updates
Company press release announcing U.S. FDA IND clearance to begin a Phase 3 trial of the neurovascular candidate in traumatic brain injury.
Press release reporting completion of enrollment in a Phase 4 post-approval study for the neurovascular candidate in acute ischemic stroke.
Press release announcing FDA Orphan Drug designation for the neurovascular candidate in neonatal HIE.
Media article reporting the first enrollment site in a Phase 3 stroke trial evaluating the company's neurovascular therapeutic.
Preclinical study reporting outcomes in a swine ventricular fibrillation model comparing adjunct resuscitation with a vasoactive agent versus control; reported differences in return of spontaneous circulation and short-term survival.
Clinical outcomes analysis examining body mass index and outcomes in out-of-hospital cardiac arrest patients.
Company press release announcing U.S. FDA IND clearance to begin a Phase 3 trial of the neurovascular candidate in traumatic brain injury.
Press release reporting completion of enrollment in a Phase 4 post-approval study for the neurovascular candidate in acute ischemic stroke.
Press release announcing FDA Orphan Drug designation for the neurovascular candidate in neonatal HIE.
Media article reporting the first enrollment site in a Phase 3 stroke trial evaluating the company's neurovascular therapeutic.
Preclinical study reporting outcomes in a swine ventricular fibrillation model comparing adjunct resuscitation with a vasoactive agent versus control; reported differences in return of spontaneous circulation and short-term survival.
Clinical outcomes analysis examining body mass index and outcomes in out-of-hospital cardiac arrest patients.